News and Trends 13 Nov 2017
British Biotech Gets PRIME Designation for its Brittle Bones Drug
…portfolio contains four clinical‑stage candidates, including BPS-804 for the treatment of osteogenesis imperfecta. The candidate has been given Prime Designation by the EMA, which means Mereo will receive scientific advice…